Fennec Pharmaceuticals Inc. FENC
Institutional shares held
14.2 Million
10K
calls
83.8K
puts
Total value of holdings
$117M
$82K
calls
$688K
puts
Market Cap
$214M
26,067,300
Shares Out.
Institutional ownership
54.46%
# of Institutions
82
We take great care to ensure that the data presented and summarized in this overview for FENNEC PHARMACEUTICALS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FENC
View all-
Southpoint Capital Advisors LP New York, NY4.08MShares$33.5 Million0.98% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$19.8 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.23MShares$18.4 Million12.03% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA967KShares$7.95 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD682KShares$5.6 Million1.04% of portfolio
-
State Street Corp Boston, MA336KShares$2.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA305KShares$2.5 Million0.0% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL288KShares$2.36 Million7.16% of portfolio
-
Morgan Stanley New York, NY254KShares$2.09 Million0.0% of portfolio
Latest Institutional Activity in FENC
Top Purchases
Top Sells
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Transactions at FENC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 10
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,775
-3.02%
|
$15,975
$9.24 P/Share
|
|
Oct 10
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
4,062
+6.46%
|
$4,062
$1.23 P/Share
|
|
Oct 09
2025
|
Southpoint Capital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,609
-0.51%
|
$185,481
$9.35 P/Share
|
|
Oct 08
2025
|
Southpoint Capital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,605
-0.48%
|
$176,445
$9.47 P/Share
|
|
Oct 08
2025
|
Rosty Raykov |
BUY
Exercise of conversion of derivative security
|
Direct |
4,609
+5.03%
|
$9,218
$2.45 P/Share
|
|
Oct 07
2025
|
Southpoint Capital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,900
-0.66%
|
$242,100
$9.59 P/Share
|
|
Oct 06
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-10.81%
|
$90,000
$9.78 P/Share
|
|
Sep 30
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,430
+1.4%
|
-
|
|
Sep 30
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+5.33%
|
-
|
|
Sep 05
2025
|
Rosty Raykov |
BUY
Exercise of conversion of derivative security
|
Direct |
36,207
+29.32%
|
$72,414
$2.45 P/Share
|
|
Sep 04
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-16.37%
|
$80,000
$8.92 P/Share
|
|
Aug 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+7.86%
|
-
|
|
Aug 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.42%
|
-
|
|
Aug 05
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-15.18%
|
$80,000
$8.09 P/Share
|
|
Jul 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.44%
|
-
|
|
Jul 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+7.33%
|
-
|
|
Jul 07
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,119
-2.0%
|
$8,952
$8.71 P/Share
|
|
Jul 07
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,127
+3.66%
|
$4,254
$2.35 P/Share
|
|
Jul 03
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-14.15%
|
$80,000
$8.61 P/Share
|
|
Jun 30
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,431
+1.47%
|
-
|
Last 12 Months Summary
Buy / Acquisition
234K
Shares
From
6
Insiders
| Exercise of conversion of derivative security | 110K shares |
|---|---|
| Open market or private purchase | 15K shares |
| Grant, award, or other acquisition | 109K shares |
Sell / Disposition
201K
Shares
From
3
Insiders
| Open market or private sale | 201K shares |
|---|